Comparison of allelic effects in Discovery + Replication meta-analysis and in C282Y homozygotes from the HEIRS study. Error bars show standard errors for betas.
Micros/EURAC
The MICROS study is part of the genomic health care program 'GenNova' and was carried out in three villages of the Val Venosta, South Tyrol (Italy), in [2001] [2002] [2003] . It comprised members of the populations of Stelvio, Vallelunga and Martello. A detailed description of the MICROS study is available elsewhere (Pattaro et al. 2007 ). Briefly, study participants were volunteers from three isolated villages located in the Italian Alps, in a German-speaking region bordering with Austria and Switzerland. Owing to geographical, historical and political reasons, the entire region experienced a prolonged period of isolation from surrounding populations. Information on the participant's health status was collected through a standardized questionnaire. Laboratory data were obtained from standard blood analyses. The study participants are connected among each other in a unique genealogy for the three villages. The study was approved by the Landesethikkomitee (ethics committee) of the autonomous province of Bolzano. 
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Other couples who lived in the Rucphen region in the southwest Netherlands and had at least 6 children baptized in the community church between 1850 and 1900 . All living descendants of these pairs (as well as their spouses), ascertained on the basis of municipal and baptismal records, were traced and invited to participate (n = 3000 ). Selection of the study participants was not based on any disease. The Medical Ethical Committee of the Erasmus Medical Center, Rotterdam approved the study and informed consent was obtained from all participants.
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Busselton Health Study
Residents of the town of Busselton in the southwest of Western Australia have been involved in a series of health surveys since 1966.a The population is predominantly of European origin. In 1994/95 there was a follow-up study involving a subset of those who had attended any of the previous surveys. Cases of asthma were defined as those who reported doctor-diagnosed asthma at any survey that they attended from 1966 to 1994 (answer 'Yes' to 'Has your doctor ever told you that you had asthma?').b Controls are those who have consistently answered 'No' to 'Has your doctor ever told you that you had asthma?' at all previous surveys that they have attended from 1996 to 1994. For the GWA study, a case control sample of unrelated individuals was selected. After QC a total of 1,207 subjects were retained in the GWAS analyses. Ethical approval was obtained through the Human Research Ethics Office, University of Western Australia Website: http://www.busseltonhealthstudy.com/ James AL, Knuiman MW, Divitini ML et al. Changes in the prevalence of asthma in adults since 1966: the Busselton Health Study. Eur Respir J 2009 The Busselton Health Study (BHS) acknowledges the generous support for the 1994/5 follow-up study from Healthway, Western Australia and the numerous Busselton community volunteers who assisted with data collection and the study participants from the Shire of Busselton. The Busselton Health Study is supported by The Great Wine Estates of the Margaret River region of Western Australia.
Replication Cohorts:
Estonian Biobank (replication cohort)
The Estonian cohort comes from the population-based biobank of the Estonian Genome Project of University of Tartu (EGCUT). The project is conducted according to the Estonian Gene Research Act and all participants have signed the broad informed consent 
InCHIANTI
The InCHIANTI study is a population-based epidemiological study aimed at evaluating the factors that influence mobility in the older population living in the Chianti region in Tuscany, Italy. During physical examination of each individual, a blood sample was collected and divided into two aliquots. One aliquot was used for DNA extraction and the other to characterize several blood phenotypes. During the study, we genotyped, by common GWAS arrays (Affymtrix 10K, Affymetrix 500K and Affymetrix 6.0), 4,694 individuals selected from the whole sample to represent the largest available families, regardless of their phenotypic values. Genotyping protocol and quality checks for the genotyping arrays were described previously [Naitza et al Plos Genet 2012] . The quality controlled 731,209 autosomal markers were used to estimate genotypes for additional 1,594,772 polymorphic SNPs assessed in the CEU HapMap population (release 22) by genotype imputation. The SardiNIA study was approved by both the IRB at the National Institute on Ageing and the local Italian Ethical Committee "Azienda Unita' Sanitaria Locale (U.S.L.) N 4, Lanusei.
computing resources made available for imputation and analysis by the CRS4 HP Computing Cluster in Pula (Cagliari, Italy), and in particular to Lidia Leoni, Luca Carta e Michele Muggiri. This work was supported by the Intramural Research Program of the National Institute on Aging (NIA), National Institutes of Health (NIH). The SardiNIA ("Progenia") team was supported by Contract NO1-AG-1-2109 from the NIA.
CoLAUS
The CoLaus study is a population-based cohort study in Lausanne, Switzerland and has been described previously [Firmann M, BMC Cardiovascular Disorders, 2008, PMID 18366642] . Briefly, the baseline study was conducted between 2003 and 2006, recruiting over 6,000 subjects. The following inclusion criteria were applied: a) voluntary participation in the examination, including blood sample, b) aged 35-75 years, and c) Caucasian origin defined as having both parents and grand-parents Caucasian (determined by birth place). A follow-up visit took place from 2009-2012, hence 5 years after the baseline study, (n=5,228, 78% follow-up) and similar measurements were repeated. The Institutional Review Board of the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne and the Cantonal Ethics Committee (Commission Cantonale d'éthique de la recherche sur l'être humain) approved the study protocol for both the baseline and follow-up studies and signed informed consent was obtained from participants.
PREVEND
The PREVEND Study is a prospective, observational cohort study, focussed to assess the impact of elevated urinary albumin loss in nondiabetic subjects on future cardiovascular and renal disease. PREVEND is an acronym for Prevention of REnal and Vascular ENdstage Disease. This study started with a population survey on the prevalence of micro-albuminuria and generation of a study cohort of the general population. The goal is to monitor this cohort for the longterm development of cardiac-, renal-and peripheral vascular end-stage disease. For that purpose the participants receive questionnaires on We thank all EPIC participants and staff for their contribution to the study. 
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